Quick Answer
Moderna, Inc. reported Cash and Equivalents of $2.60 billion for fiscal year 2025.
Moderna, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $2.60B | +34.7% |
| 2024 | $1.93B | -33.7% |
| 2023 | $2.91B | -9.3% |
| 2022 | $3.21B | -53.2% |
| 2021 | $6.85B | +161.0% |
| 2020 | $2.62B | +1011.9% |
| 2019 | $236.00M | -64.2% |
| 2018 | $658.36M | +388.2% |
| 2017 | $134.86M | +169.3% |
| 2016 | $50.08M | -68.5% |
| 2015 | $159.04M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.13B | -31.1% | -11.5% |
| June 30, 2025 | $1.28B | -48.4% | -21.2% |
| March 31, 2025 | $1.62B | -20.9% | -15.8% |
| December 31, 2024 | $1.93B | -33.7% | +17.2% |
| September 30, 2024 | $1.64B | -43.9% | -33.7% |
| June 30, 2024 | $2.48B | -34.8% | +20.8% |
| March 31, 2024 | $2.05B | -40.4% | -29.4% |
| December 31, 2023 | $2.91B | -9.3% | -0.9% |
- Moderna, Inc. showed an increase of +34.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2015–2025 period, Moderna, Inc.’s cash and equivalents has grown by 1531.6% (from $159.04 million to $2.60 billion).
- The most recent figure is from Moderna, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 20, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: